The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2019 | Managing CRS after anti-BCMA CAR-T for myeloma
He Huang
• 17 May 2019
He Huang, MD, PhD, of Zhejiang University School of Medicine, Zhejiang, China discusses how the majority of patients receiving BCMA CAR-T therapies suffer from cytokine release syndrome (CRS). Dr Huang also discusses different treatments including the anti-interleukin-6 antibodies. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
